Use of oral corticosteroids in the United Kingdom

被引:401
作者
van Staa, TP
Leufkens, HGM
Abenhaim, L
Begaud, B
Zhang, B
Cooper, C [1 ]
机构
[1] Univ Southampton, Southampton Gen Hosp, MRC, Environm Epidemiol Unit, Southampton SO16 6YD, Hants, England
[2] Procter & Gamble Pharmaceut, Staines, England
[3] Univ Utrecht, Dept Pharmacoepidemiol & Pharmacotherapy, NL-3508 TC Utrecht, Netherlands
[4] Sir Mortimer B Davis Jewish Hosp, Ctr Clin Epidemiol & Community Studies, Montreal, PQ H3T 1E2, Canada
[5] McGill Univ, Dept Epidemiol & Biostat, Montreal, PQ, Canada
[6] CHU, Ctr Pharmacovigilance, Bordeaux, France
来源
QJM-MONTHLY JOURNAL OF THE ASSOCIATION OF PHYSICIANS | 2000年 / 93卷 / 02期
关键词
D O I
10.1093/qjmed/93.2.105
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Administration of oral corticosteroids is associated with the development of osteoporosis and an increased risk of fractures. However, the size of the treated sub-population who would benefit from preventive therapy remains uncertain. The objective of this study was to investigate the usage pattern of oral corticosteroids in a large sample representative of the general population in England and Wales. Information was obtained from the General Practice Research Database (GPRD) which contains medical records of general practitioners. Oral corticosteroid users were patients aged 18 years or older who received one or more prescriptions for oral corticosteroids. Over 1.6 million oral corticosteroid prescriptions were issued to the cohort of 244 235 oral corticosteroid users. At any point in time, oral corticosteroids were being used by 0.9% of the total adult GPRD population. The highest use (2.5%) was by people between 70 and 79 years of age. Respiratory disease was the most frequently recorded indication for oral corticosteroid treatment (40%). Patients with arthropathies were most likely to use long-term, continuous treatment, and patients with chronic obstructive pulmonary disease least likely (19.3% and 6.1%, respectively, used oral corticosteroids for more than 2 years). The overall use of bone-active medication (oestrogens, bisphosphonates, vitamin D, and calcitonin) during oral corticosteroid treatment was low (between 4.0% and 5.5%). The current population in the UK at risk of developing corticosteroid-induced fractures might be as large as 350000. Identification of these patients will be important for implementing preventive strategies in a cost-effective manner.
引用
收藏
页码:105 / 111
页数:7
相关论文
共 33 条
[1]  
[Anonymous], 1994, Pharmacoepidemiology) and Drug Safety
[2]  
*BRIT MED ASS ROYA, 1996, BRIT NAT FORM, V32
[3]  
BUTLER RC, 1991, BRIT J RHEUMATOL, V30, P86
[4]  
COMPSTON JE, 1995, ALIMENT PHARM THER, V9, P237
[6]   RHEUMATOID-ARTHRITIS, CORTICOSTEROID-THERAPY AND HIP FRACTURE [J].
COOPER, C ;
COUPLAND, C ;
MITCHELL, M .
ANNALS OF THE RHEUMATIC DISEASES, 1995, 54 (01) :49-52
[7]   THE RISKS OF LOCAL AND SYSTEMIC CORTICOSTEROID ADMINISTRATION [J].
COOPER, C ;
KIRWAN, JR .
BAILLIERES CLINICAL RHEUMATOLOGY, 1990, 4 (02) :305-332
[8]  
DEQUEKER J, 1995, J RHEUMATOL, V22, P1013
[9]  
Dequeker J, 1995, Clin Exp Rheumatol, V13 Suppl 12, pS21
[10]   A UK Consensus Group on management of glucocorticoid-induced osteoporosis: an update [J].
Eastell, R ;
Reid, DM ;
Compston, J ;
Cooper, C ;
Fogelman, I ;
Francis, RM ;
Hosking, DJ ;
Purdie, DW ;
Ralston, SH ;
Reeve, J ;
Russell, RGG ;
Stevenson, JC ;
Torgerson, DJ .
JOURNAL OF INTERNAL MEDICINE, 1998, 244 (04) :271-292